Light Therapy and Binge Eating Disorder Treatment (BED Light Study)

June 17, 2021 updated by: Hospices Civils de Lyon

Interest of Light Therapy in the Treatment of Binge Eating Disorder: Prospective Controlled Randomized Double-blind Trial

Binge Eating Disorder (BED) is the most widespread food behavior disorder, with prevalence three times higher than anorexia. Its pathophysiology remains poorly understood and the investigators have few therapeutic options. Following a review of the literature, the investigators hypothesize that luminotherapy could be an innovative treatment of BED by its favorable effect on triggers of hyperphagic access, circadian disturbances, attention and impulsivity. The study is prospective, interventional, randomized, double-blind, monocentric (HCL). 52 patients with BED will be randomized to an active arm with intensive luminotherapy (1 daily 30 min, 10,000 lux in the morning) versus a placebo arm (<500 lux). Treatment will be delver every day during 30 days. Assessments will take place on D0, D30 and D60. The main objective is to compare the evolution of the number of hyperphagic access before and after treatment between the two groups. Secondary objectives are to compare characteristics of hyperphagic access, bodily concerns, food dependence and impulsivity, mood, anxiety, cognitive and attentional profiles (STROOP, Go / No Go, SST, BART, Prospective Time Estimation Task, Switching Task), liking / wanted for different food categories and carbohydrate metabolism (CRP, glucose, insulinemia, insulin resistance, profile of lipid abnormalities, 25-OH vitamin D3).

Study Overview

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69500
        • HCL Centre REférent pour l'Anorexie et les Troubles du Comportement Alimentaire de Lyon (CREATyon)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged between 18 and 55 years old
  • Binge eating disorders or other eating disorders according to DSM V criteria
  • Patient with BES score (with " Bing Eating Scale " ) > 18
  • Patient with BMI > 18.5 kg/m2
  • Patient who agrees to be included in the study and who signs the informed consent form
  • Patient affiliated to a healthcare insurance plan

Exclusion Criteria:

  • Patients with other psychiatric comorbidities, including a disorder bipolar mood
  • Unstabilized diabetic patient with or retinopathy
  • Patient with sleep disorder (delay or phase inversion)
  • Patient with psychotropic treatment unstabilized (except anxiolytic treatment)
  • Recent eye surgery or eye problem preventing exposure to bright light.
  • Medication making the skin more sensitive to light (eg. Tablets against malaria)
  • Patient who does not understand French/is unable to give consent
  • Mentally unbalanced patients, under supervision or guardianship
  • Patient already included in a research study
  • Pregnancy or desire to be pregnant during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: High intensity light therapy
Treatment with light therapy in high intensity (10,000 lux)

Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.

Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position.

PLACEBO_COMPARATOR: Low intensity light therapy
Treatment with light therapy in low intensity (<500 lux)

Treatment with light therapy in low intensity (<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.

Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and discontinuation of treatment
Time Frame: Day-7 to Day-1 period (before Day 0) compared to Day23 to Day30 period (after Day 0)
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
Day-7 to Day-1 period (before Day 0) compared to Day23 to Day30 period (after Day 0)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and 30 days after discontinuation of treatment
Time Frame: Day-7 to Day-1 period compared to Day23 to Day30 period
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
Day-7 to Day-1 period compared to Day23 to Day30 period
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 0
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
Day 0
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 30
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
Day 30
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 60
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
Day 60
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 0
Evaluation of the duration,by the crisis agenda.
Day 0
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 30
Evaluation of the duration,by the crisis agenda.
Day 30
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 60
Evaluation of the duration,by the crisis agenda.
Day 60
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 0
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
Day 0
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 30
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
Day 30
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 60
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
Day 60
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 0
Evaluation of the factors triggering by the "START" scale.
Day 0
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 30
Evaluation of the factors triggering by the "START" scale.
Day 30
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 60
Evaluation of the factors triggering by the "START" scale.
Day 60
Characteristics of hyperphagic access (severity of the disorder, duration of crisis, amount of food ingested and evolution of factors triggering)
Time Frame: Day 30
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale. Evaluation of the duration, the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda. Evaluation of the factors triggering by the "START" scale.
Day 30
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and 30 days after discontinuation of treatment
Time Frame: Day-7 to Day-1 period (before Day 0) compared to Day53 to Day60 period (after Day 0)
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
Day-7 to Day-1 period (before Day 0) compared to Day53 to Day60 period (after Day 0)
Symptomatic development of BED
Time Frame: Day 0

The symptomatic development of BED will be measured by evaluating :

  • The psychopathology of the BED from the Eating Disorder Inventory 2 questionnaire
  • The Body concerns based on the "Body sharpe" questionnaire
  • The Addiction to food from the Yale Food Addiction scale
  • The Diet-related impulsivity from the Three-Factor Eating Questionnaire
Day 0
Symptomatic development of BED
Time Frame: Day 30

The symptomatic development of BED will be measured by evaluating the composite:

  • The psychopathology of the BED from the Eating Disorder Inventory 2 questionnaire
  • The Body concerns based on the "Body sharpe" questionnaire
  • The Addiction to food from the Yale Food Addiction scale
  • The Diet-related impulsivity from the Three-Factor Eating Questionnaire
Day 30
Symptomatic development of BED
Time Frame: Day 60

The symptomatic development of BED will be measured by evaluating the composite:

  • The psychopathology of the BED from the Eating Disorder Inventory 2 questionnaire
  • The Body concerns based on the "Body sharpe" questionnaire
  • The Addiction to food from the Yale Food Addiction scale
  • The Diet-related impulsivity from the Three-Factor Eating Questionnaire
Day 60
Evolution of other psychological parameters related to BED
Time Frame: Day 0
The evolution of other psychological parameters will be measured by evaluating the composite :the mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
Day 0
Evolution of other psychological parameters related to BED
Time Frame: Day 30
The evolution of other psychological parameters will be measured by evaluating the composite the mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
Day 30
Evolution of other psychological parameters related to BED
Time Frame: Day 60
The evolution of other psychological parameters will be measured by evaluating the composite mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
Day 60
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 0
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed. The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
Day 0
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 30
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed. The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
Day 30
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 60
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed. The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
Day 60
Evolution of appetite for different categories of food
Time Frame: Day 0
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ). A description of the test is available at: https://www.millisecond.com/download/library/
Day 0
Evolution of appetite for different categories of food
Time Frame: Day 30
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ). A description of the test is available at: https://www.millisecond.com/download/library/
Day 30
Evolution of appetite for different categories of food
Time Frame: Day 60
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ). A description of the test is available at: https://www.millisecond.com/download/library/
Day 60
Biological parameters may be impacted or mediated by part of the treatment efficiency
Time Frame: Day 0
Inflammation parameters, glucose, insulinemia, insulin resistance, Profile of lipid abnormalities, 1-25-OH vitamin D3
Day 0
Biological parameters may be impacted or mediated by part of the treatment efficiency
Time Frame: Day 30
Inflammation parameters, glucose, insulinemia, insulin resistance, Profile of lipid abnormalities, 1-25-OH vitamin D3
Day 30
Weight (kilogramm)
Time Frame: Day 0
Weight will be expressed in absolute value
Day 0
Weight (kilogramm)
Time Frame: Day 30
Weight will be expressed in absolute value
Day 30
Weight (kilogramm)
Time Frame: Day 60
Weight will be expressed in absolute value
Day 60
Observance rate to light therapy
Time Frame: day1 to day30
The assessment of the adherence rate will be quantified by the average number of lux received over the 30 days of treatment. The exposure (expressed in lux number / session) in lux will be measured and recorded using a luxmeter
day1 to day30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Diane MORFIN, MD, Hospices Civils de Lyon Centre REférent pour l'Anorexie et les Troubles du Comportement Alimentaire de Lyon (CREATyon)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 29, 2018

Primary Completion (ACTUAL)

April 9, 2020

Study Completion (ACTUAL)

April 9, 2020

Study Registration Dates

First Submitted

March 9, 2017

First Submitted That Met QC Criteria

March 22, 2017

First Posted (ACTUAL)

March 29, 2017

Study Record Updates

Last Update Posted (ACTUAL)

June 18, 2021

Last Update Submitted That Met QC Criteria

June 17, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 69HCL16_0626
  • 2016-A01768-43 (OTHER: ID-RCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Binge-Eating Disorder

Clinical Trials on High intensity bright light therapy

Subscribe